Stockreport

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights [Yahoo! Finance]

Tvardi Therapeutics, Inc.  (TVRD) 
PDF Topline healthy volunteer data from Phase 1 study of next-generation STAT3 inhibitor, TTI-109, on track for H1 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi [Read more]